VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYNB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYNBKyntra Bio, Inc.
$2.04$15M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYNBCash Flow

Kyntra Bio, Inc. (KYNB) Cash Flow Statement

14Y historyFree accessUpdated daily

Free cash flow has oscillated from -$39.9M in 2024Q2 to +$12.7M in 2025Q2 and back to -$12.2M in 2026Q3, with an OCF-to-net-income ratio of -0.01 in 2025Q3 indicating reported profits were not backed by operating cash, warranting further investigation of timing effects.

Income StatementBalance SheetCash FlowRatios

KYNB Cash Flow Statement

Annual statement

KYNB Cash Flow Statement

Kyntra Bio, Inc. (KYNB) cash flow statement — 14-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash from Operations-48.45M-4.77M-138M-315.02M-145.93M-82.23M81.6M-78.7M-76.14M-66.51M7.11M-18.57M22.41M25.92M-5.61M
Operating CF Margin %--74.13%-465.88%-673.08%-103.69%-34.95%46.28%-30.68%-35.76%-52.93%3.96%-10.27%16.29%25.37%-8.5%
Operating CF Growth %-1265.33%96.54%56.19%-115.87%-77.46%-200.77%203.68%-3.36%-14.48%-1035.75%--182.85%-13.52%562.41%-
Net Income34.88M183.45M-47.58M-284.23M-293.65M-290.02M-189.29M-76.97M-86.42M-120.88M-58.07M-85.78M-59.5M-14.94M-32.57M
Depreciation & Amortization28K748K2.69M9.93M10.6M14.81M22.05M21.45M6.56M6.1M6.04M5.68M4.47M5.08M5.6M
Stock-Based Compensation4.34M6.58M25.21M50.77M65.6M71.16M72.72M66.27M52.14M37.54M32.13M27.68M18.7M3.44M4.56M
Deferred Taxes0000000000-211K0000
Other Non-Cash Items-45.04M-42.52M-868K28.2M1.09M61.74M1.5M-3.8M-30K1.71M2.69M2.89M648K539K542K
Working Capital Changes9.51M-153.03M-117.46M-119.69M70.43M60.08M174.63M-85.66M-48.4M9.02M24.52M30.96M58.1M31.79M16.27M
Change in Receivables-3.73M-2.54M-6.74M3.43M765K25.18M-11.97M35.23M-55.23M2M4.96M-1.95M4.04M-8.71M14.15M
Change in Inventory610K5.36M22.28M-1.7M-11M-14.16M-9.18M-6.89M0000000
Change in Payables-512K-27.65M14.51M-15.51M5.91M805K17.73M-3.05M3.63M-714K-298K1.97M3.48M-2.04M770K
Cash from Investing-16.72M35.42M125.99M153.66M89.12M-426.97M452.49M120.02M-522.12M69.87M6.62M-5.87M-107.29M10.78M19.15M
Capital Expenditures0-38K-266K-2.52M-3.74M-5.19M-3.99M-5.76M-8.02M-8.5M-1.25M-1.98M-8.12M-6.81M-744K
CapEx % of Revenue0%0.59%0.9%5.38%2.66%2.2%2.27%2.25%3.77%6.76%0.7%1.09%5.9%6.66%1.13%
Acquisitions3.93M01.05M656K00-2.83M00000000
Investments---------------
Other Investing6.41M96.61M00-34.99M-25M07K184K5K02K10K2K2K
Cash from Financing-42.82M-86.03M-255K122.75M46.78M-563K13.34M-4.3M13.88M496.47M6.74M12.35M174.09M680K6.81M
Debt Issued (Net)-6K-80.56M-40K73.59M-538K-5.89M-13.02M-12.33M-360K-403K-403K-403K-403K421K-714K
Equity Issued (Net)-20K-69K139K48.41M4.18M12.7M37.83M20.78M29.85M506.12M9.88M1000K1000K84K0
Dividends Paid00-2.23M000000000000
Share Repurchases-20K-69K0000000000000
Other Financing-42.8M-5.4M1.88M748K43.13M-7.37M-11.46M-12.75M-15.61M-9.24M-2.74M-2.24M16.86M175K7.52M
Net Change in Cash-108.07M-54.31M-11.51M-42.01M-15.52M-507.17M552.13M37.01M-584.4M499.88M20.46M-12.13M89.12M37.46M20.29M
Free Cash Flow-48.45M-4.81M-138.26M-317.54M-184.67M-112.42M77.61M-84.47M-84.16M-75.01M5.86M-20.55M14.3M19.11M-6.35M
FCF Margin %-913.65%-74.72%-466.78%-678.46%-131.22%-47.77%44.02%-32.92%-39.52%-59.69%3.26%-11.36%10.39%18.71%-9.63%
FCF Growth %-183.49%96.52%56.46%-71.95%-64.27%-244.85%191.88%-0.36%-12.2%-1380.96%--243.73%-25.2%401.02%-
FCF per Share-11.96-1.19-34.55-81.59-49.33-30.4321.59-24.37-25.03-25.692.33-0.340.250.40-0.48
FCF Conversion (FCF/Net Income)-1.39x-0.03x2.90x1.11x0.50x0.28x-0.43x1.02x0.88x0.53x-0.12x0.22x-0.38x-1.73x0.17x
Interest Paid00054K104K94K135K174K218K255K295K335K377K-433K506K
Taxes Paid000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Decoupled From Operating Cash

According to the reported cash flow statements, KYNB posted net income of $148.5M in 2025Q3 while operating cash flow was negative $1.8M, an OCF-to-net-income ratio of -0.01 that signals profits were not backed by cash generation.

The gap between reported net income and operating cash flow is the central issue in this dataset, with several quarters showing positive earnings alongside cash outflows. The $148.5M quarterly profit in 2025Q3 appears to be driven by non-cash or non-operating items, since working capital changes of negative $160.3M were the dominant reconciling item rather than underlying operations. Investors should monitor whether these earnings reflect durable economics or accounting-driven swings that do not translate into cash.

Free Cash Flow Oscillates Without Direction

Based on reported figures, KYNB's free cash flow swung from negative $39.9M in 2024Q2 to positive $12.7M in 2025Q2 and back to negative $12.2M in 2026Q3, with FCF margins ranging from negative 172.5% to positive 98.7%.

The FCF series shows no stable trend, and the extreme margin range reflects the company's small and volatile revenue base rather than consistent cash economics. Quarters of positive FCF, such as 2025Q1 and 2025Q2, appear to be exceptions within a longer pattern of cash consumption. The recent 2026Q3 burn of $12.2M suggests the most recent operating trajectory has reverted toward negative cash generation, which warrants further investigation.

Working Capital Swings Dominate Cash Results

As reported in the cash flow statements, working capital changes ranged from negative $160.3M in 2025Q3 to positive $17.8M in 2025Q2, indicating that balance sheet timing has been a larger driver of reported cash flow than core operating activity.

Working capital movements are large relative to operating cash flow in most periods, which makes the reported operating results difficult to interpret on a recurring basis. The 2025Q3 outflow of $160.3M against only $1.8M of operating cash burn implies that other operating assets or liabilities were absorbing substantial cash, though the composition is not disclosed in the supplied data. This pattern may indicate timing effects rather than structural cash generation.

Cumulative Cash Burn Outweighs Reported Profits

Across the ten reported quarters, KYNB's cumulative operating cash flow appears negative, while cumulative net income is distorted by a single large positive quarter, based on the figures supplied.

Summing the quarterly operating cash flows shows net consumption over the window, which contrasts with the $148.5M and $37.9M profit quarters that dominate reported earnings. The divergence suggests that reported profitability is concentrated in a few periods and is not representative of sustained cash generation. Investors should treat the earnings figures with caution until the cash conversion pattern stabilizes.

Positive Quarters May Mask Underlying Burn

The strongest counterpoint is that KYNB's 2025 positive free cash flow quarters may reflect timing rather than durable generation, given the 2026Q3 reversal to negative $12.2M and the absence of any capex or disclosed capital return activity.

Two quarters of positive FCF in 2025 could be read as an emerging inflection, but the subsequent negative quarters and the recent $12.2M burn weaken that interpretation. With capital expenditures near zero and no dividends or buybacks, the cash balance trajectory depends on working capital timing and financing activity not captured in this dataset. The available figures do not establish whether the company has access to external funding, so that factor remains unassessed here.

KYNB — Frequently Asked Questions

Quick answers to the most common questions about buying KYNB stock.

How much cash does Kyntra Bio, Inc. (KYNB) generate from operations?

Kyntra Bio, Inc. (KYNB) generated $-4.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Kyntra Bio, Inc.'s free cash flow?

Kyntra Bio, Inc. (KYNB) reported negative free cash flow of $4.8M in 2025, indicating capital requirements exceeded cash from operations.

What is Kyntra Bio, Inc.'s capital expenditure (CapEx)?

Kyntra Bio, Inc. (KYNB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Kyntra Bio, Inc. distribute cash to shareholders?

In 2025, Kyntra Bio, Inc. (KYNB) spent $0.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.